We’re excited to announce our new brand identity to reflect a stronger, more focused, and modern representation of our team and company.
What started as an idea between friends in 2004, has come a long way to today with a fully remote, global team of 135+ (and counting). Larvol empowers healthcare and life sciences experts to improve their strategic decision-making by providing them with custom intelligence reports and SaaS solutions that are accurate, rapid, and expertly curated. Our four core products – Pulse, Conference, Omni, and Veri continue to add significant value to our industry and exemplify our commitment to providing outstanding products to our customers.
We’re excited to announce our new brand identity to reflect a stronger, more focused, and modern representation of our team and company in several ways:
Watch the video where Bruno talks about our brand-
A new logo demonstrating our focus on simplicity.
A relaunched website with an improved design, fresh look, and branding. Our website has been streamlined to find useful information quickly on products and features and provides an enhanced user experience. We’ve added to our team section to get to know the team behind it all. Get to know us more here. We’re adding new segmentation for our Blog and Top News sections to easier find information, articles, and news releases for the latest in healthcare and pharma spaces.
A new motto as mentioned earlier, “Semper Tigris” putting in the spotlight who we are at Larvol. The tiger has featured prominently internally as our “spirit animal” defining our razor-sharp focus, fearless approach to our work, and speed.
Our social media pages will undergo rebranding as well with added focus on unique content as well as updates and announcements. Don’t miss out on any action, follow us here: Facebook, Twitter, LinkedIn & Instagram.
Change is the only constant, but what our values including customer focus, innovation, and respect for people remain unchanged. We continue to create robust, scalable, high-quality intelligence tools for the pharmaceutical, life sciences, and healthcare industry and will be expanding our portfolio to include solutions focused on cancer data research.
We’re incredibly proud of the work we do at Larvol, and are thankful to all our stakeholders (customers, partners, and “Tigers” ) who have accompanied us in our growth. If you wish to know more connect with us at info@larvol.com.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm